NR565 ADVANCED PHARMACOLOGY FUNDAMENTALS (FNP/AGACNP) MIDTERM
PRACTICE EXAM REVIEW QUESTIONS AND ANSWERS | COMPREHENSIVE STUDY
GUIDE | UPDATED 2026/2027
Examiner/Administrator: Academic Nurse Practitioner Pharmacology Curriculum
Committee (Graduate Nursing Programs)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
NR565 ADVANCED PHARMACOLOGY FUNDAMENTALS (FNP/AGACNP) MIDTERM
PRACTICE EXAM
2026/2027 EDITION
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
COMPLETE PRACTICE EXAM
100 MULTIPLE-CHOICE QUESTIONS
EXACT OFFICIAL COUNT: 100 QUESTIONS || PASSING SCORE: 70% || TESTING TIME:
120 MINUTES || GRADUATE NURSING PHARMACOLOGY CURRICULUM ALIGNMENT ||
EVIDENCE-BASED PRESCRIBING PRINCIPLES || ADVANCED PRACTICE NURSING
PHARMACOTHERAPEUTICS || COMPREHENSIVE EXAM PREPARATION STUDY GUIDE ||
EDUCATIONAL USE ONLY || PREPARED FOR GRADUATE NURSING COMPETENCY
DEVELOPMENT || PROFESSIONAL ASSESSMENT MATERIAL
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Pharmacokinetics, Pharmacodynamics & Core Principles (Q1–Q10)
Q1. A 72-year-old patient with chronic kidney disease (eGFR 28 mL/min) is prescribed a
medication that is primarily eliminated by renal excretion. What is the most
appropriate initial prescribing action?
A. Start at standard adult dose
B. Increase dosing frequency
C. Reduce dose or extend dosing interval
D. Switch to a hepatic-metabolized drug without evaluation
Correct Answer: 🔴 C. Reduce dose or extend dosing interval
,Explanation: 🔹 In renal impairment, drug clearance is reduced, increasing risk of
toxicity. Dose reduction or interval extension helps maintain therapeutic levels without
accumulation. Option A increases toxicity risk. Option B worsens accumulation. Option D
may be appropriate in some cases but requires full clinical evaluation before substitution.
Q2. A drug with high protein binding is administered to a patient with
hypoalbuminemia. What is the expected pharmacologic effect?
A. Decreased free drug concentration
B. Increased free (active) drug concentration
C. No change in drug activity
D. Complete drug inactivation
Correct Answer: 🔴 B. Increased free (active) drug concentration
Explanation: 🔹 Low albumin reduces binding sites, increasing free drug fraction and risk
of toxicity. Protein-bound drug is inactive; thus, decreased binding increases
pharmacologic effect. A and C are incorrect as binding dynamics are altered. D is
incorrect because drug remains active.
Q3. A nurse practitioner prescribes a medication with a narrow therapeutic index. What
is the priority monitoring strategy?
A. Monitor for dietary interactions only
B. Routine therapeutic drug level monitoring
C. Monitor only clinical symptoms
D. No monitoring is required after steady state
Correct Answer: 🔴 B. Routine therapeutic drug level monitoring
Explanation: 🔹 Narrow therapeutic index drugs require serum level monitoring to avoid
toxicity or subtherapeutic dosing. Clinical symptoms alone are insufficient. Dietary
monitoring is supportive but not primary. No monitoring is unsafe.
Q4. Which factor most significantly affects first-pass metabolism?
,A. Route of administration
B. Age only
C. Protein binding
D. Drug color and formulation
Correct Answer: 🔴 A. Route of administration
Explanation: 🔹 Oral medications undergo hepatic first-pass metabolism, reducing
bioavailability. IV administration bypasses this effect. Age and protein binding influence
metabolism but not first-pass effect directly.
Q5. A patient is prescribed a CYP3A4 inhibitor. What is the expected effect on co-
administered drugs metabolized by CYP3A4?
A. Decreased plasma concentration
B. Increased plasma concentration
C. No pharmacokinetic change
D. Increased renal clearance
Correct Answer: 🔴 B. Increased plasma concentration
Explanation: 🔹 CYP3A4 inhibition slows metabolism, increasing drug levels and toxicity
risk. A is incorrect as metabolism decreases. C is incorrect due to enzyme interaction. D is
unrelated to hepatic metabolism.
Q6. What best describes pharmacodynamics?
A. The movement of drugs through the body
B. The study of drug effects on the body
C. The study of drug excretion pathways
D. The formulation of drug compounds
Correct Answer: 🔴 B. The study of drug effects on the body
Explanation: 🔹 Pharmacodynamics describes receptor binding, drug action, and
physiologic response. A describes pharmacokinetics. C is elimination. D is pharmaceutical
chemistry.
, Q7. A patient develops tolerance to an opioid medication. What is the best
explanation?
A. Increased receptor sensitivity
B. Decreased receptor response over time
C. Complete drug elimination failure
D. Increased drug absorption
Correct Answer: 🔴 B. Decreased receptor response over time
Explanation: 🔹 Tolerance occurs due to receptor downregulation or adaptation. A is
opposite. C relates to excretion. D does not explain tolerance.
Q8. Which phase of drug metabolism typically converts lipophilic drugs into more
polar compounds?
A. Phase I oxidation/reduction
B. Phase II conjugation
C. Phase III elimination
D. Absorption phase
Correct Answer: 🔴 A. Phase I oxidation/reduction
Explanation: 🔹 Phase I introduces reactive or polar groups via oxidation/reduction.
Phase II further conjugates drugs. Phase III is transport/excretion.
Q9. A drug’s half-life increases significantly in hepatic disease. What is the most likely
cause?
A. Increased hepatic metabolism
B. Reduced hepatic clearance
C. Increased protein synthesis
D. Enhanced renal filtration
Correct Answer: 🔴 B. Reduced hepatic clearance
PRACTICE EXAM REVIEW QUESTIONS AND ANSWERS | COMPREHENSIVE STUDY
GUIDE | UPDATED 2026/2027
Examiner/Administrator: Academic Nurse Practitioner Pharmacology Curriculum
Committee (Graduate Nursing Programs)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
NR565 ADVANCED PHARMACOLOGY FUNDAMENTALS (FNP/AGACNP) MIDTERM
PRACTICE EXAM
2026/2027 EDITION
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
COMPLETE PRACTICE EXAM
100 MULTIPLE-CHOICE QUESTIONS
EXACT OFFICIAL COUNT: 100 QUESTIONS || PASSING SCORE: 70% || TESTING TIME:
120 MINUTES || GRADUATE NURSING PHARMACOLOGY CURRICULUM ALIGNMENT ||
EVIDENCE-BASED PRESCRIBING PRINCIPLES || ADVANCED PRACTICE NURSING
PHARMACOTHERAPEUTICS || COMPREHENSIVE EXAM PREPARATION STUDY GUIDE ||
EDUCATIONAL USE ONLY || PREPARED FOR GRADUATE NURSING COMPETENCY
DEVELOPMENT || PROFESSIONAL ASSESSMENT MATERIAL
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Pharmacokinetics, Pharmacodynamics & Core Principles (Q1–Q10)
Q1. A 72-year-old patient with chronic kidney disease (eGFR 28 mL/min) is prescribed a
medication that is primarily eliminated by renal excretion. What is the most
appropriate initial prescribing action?
A. Start at standard adult dose
B. Increase dosing frequency
C. Reduce dose or extend dosing interval
D. Switch to a hepatic-metabolized drug without evaluation
Correct Answer: 🔴 C. Reduce dose or extend dosing interval
,Explanation: 🔹 In renal impairment, drug clearance is reduced, increasing risk of
toxicity. Dose reduction or interval extension helps maintain therapeutic levels without
accumulation. Option A increases toxicity risk. Option B worsens accumulation. Option D
may be appropriate in some cases but requires full clinical evaluation before substitution.
Q2. A drug with high protein binding is administered to a patient with
hypoalbuminemia. What is the expected pharmacologic effect?
A. Decreased free drug concentration
B. Increased free (active) drug concentration
C. No change in drug activity
D. Complete drug inactivation
Correct Answer: 🔴 B. Increased free (active) drug concentration
Explanation: 🔹 Low albumin reduces binding sites, increasing free drug fraction and risk
of toxicity. Protein-bound drug is inactive; thus, decreased binding increases
pharmacologic effect. A and C are incorrect as binding dynamics are altered. D is
incorrect because drug remains active.
Q3. A nurse practitioner prescribes a medication with a narrow therapeutic index. What
is the priority monitoring strategy?
A. Monitor for dietary interactions only
B. Routine therapeutic drug level monitoring
C. Monitor only clinical symptoms
D. No monitoring is required after steady state
Correct Answer: 🔴 B. Routine therapeutic drug level monitoring
Explanation: 🔹 Narrow therapeutic index drugs require serum level monitoring to avoid
toxicity or subtherapeutic dosing. Clinical symptoms alone are insufficient. Dietary
monitoring is supportive but not primary. No monitoring is unsafe.
Q4. Which factor most significantly affects first-pass metabolism?
,A. Route of administration
B. Age only
C. Protein binding
D. Drug color and formulation
Correct Answer: 🔴 A. Route of administration
Explanation: 🔹 Oral medications undergo hepatic first-pass metabolism, reducing
bioavailability. IV administration bypasses this effect. Age and protein binding influence
metabolism but not first-pass effect directly.
Q5. A patient is prescribed a CYP3A4 inhibitor. What is the expected effect on co-
administered drugs metabolized by CYP3A4?
A. Decreased plasma concentration
B. Increased plasma concentration
C. No pharmacokinetic change
D. Increased renal clearance
Correct Answer: 🔴 B. Increased plasma concentration
Explanation: 🔹 CYP3A4 inhibition slows metabolism, increasing drug levels and toxicity
risk. A is incorrect as metabolism decreases. C is incorrect due to enzyme interaction. D is
unrelated to hepatic metabolism.
Q6. What best describes pharmacodynamics?
A. The movement of drugs through the body
B. The study of drug effects on the body
C. The study of drug excretion pathways
D. The formulation of drug compounds
Correct Answer: 🔴 B. The study of drug effects on the body
Explanation: 🔹 Pharmacodynamics describes receptor binding, drug action, and
physiologic response. A describes pharmacokinetics. C is elimination. D is pharmaceutical
chemistry.
, Q7. A patient develops tolerance to an opioid medication. What is the best
explanation?
A. Increased receptor sensitivity
B. Decreased receptor response over time
C. Complete drug elimination failure
D. Increased drug absorption
Correct Answer: 🔴 B. Decreased receptor response over time
Explanation: 🔹 Tolerance occurs due to receptor downregulation or adaptation. A is
opposite. C relates to excretion. D does not explain tolerance.
Q8. Which phase of drug metabolism typically converts lipophilic drugs into more
polar compounds?
A. Phase I oxidation/reduction
B. Phase II conjugation
C. Phase III elimination
D. Absorption phase
Correct Answer: 🔴 A. Phase I oxidation/reduction
Explanation: 🔹 Phase I introduces reactive or polar groups via oxidation/reduction.
Phase II further conjugates drugs. Phase III is transport/excretion.
Q9. A drug’s half-life increases significantly in hepatic disease. What is the most likely
cause?
A. Increased hepatic metabolism
B. Reduced hepatic clearance
C. Increased protein synthesis
D. Enhanced renal filtration
Correct Answer: 🔴 B. Reduced hepatic clearance
